力生制药(002393) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥254,078,179.95, a decrease of 11.56% compared to the same period last year[6] - Net profit attributable to shareholders increased by 520.81% to ¥252,483,963.51 for the quarter[6] - The basic earnings per share (EPS) rose to ¥1.37, reflecting a 522.73% increase year-on-year[6] - Total operating revenue for the current period reached ¥911,572,469.80, an increase from ¥902,020,309.45 in the previous period, representing a growth of approximately 1.73%[21] - Operating profit surged to ¥403,726,568.31, compared to ¥138,981,098.89 in the prior period, indicating a significant increase of approximately 189.66%[21] - Net profit for the current period was ¥342,666,216.18, up from ¥112,623,728.95, marking an increase of around 203.06%[22] - Basic and diluted earnings per share for the current period were both ¥1.86, compared to ¥0.62 in the previous period, reflecting an increase of approximately 200%[22] Cash Flow and Assets - Cash flow from operating activities decreased by 58.64% to ¥81,968,221.13[6] - Cash flow from operating activities generated a net cash inflow of ¥81,968,221.13, down from ¥198,170,319.93 in the previous period, a decline of about 58.69%[25] - Cash flow from investing activities showed a net inflow of ¥319,364,588.26, a significant improvement compared to a net outflow of ¥322,736,310.16 in the prior period[25] - The company reported cash and cash equivalents at the end of the period amounting to ¥2,115,199,423.12, an increase from ¥1,448,245,422.50 at the end of the previous period[25] - Cash and cash equivalents increased to CNY 2,124,872,530.21 from CNY 1,793,291,777.97, reflecting a rise of about 18.5%[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,561,717,405.65, an increase of 5.12% from the end of the previous year[6] - Total assets as of September 30, 2023, amounted to CNY 5,561,717,405.65, an increase from CNY 5,291,039,548.29 at the beginning of the year[19] - Current assets reached CNY 3,015,510,596.52, up from CNY 2,625,403,269.58 at the start of the year, indicating a growth of approximately 14.8%[17] - Total liabilities decreased slightly to CNY 919,455,826.18 from CNY 941,660,896.69, showing a reduction of approximately 2.3%[18] - The company's total equity rose to CNY 4,642,261,579.47, compared to CNY 4,349,378,651.60 at the beginning of the year, marking an increase of about 6.7%[19] Shareholder Information - The company reported a total of 19,909 common shareholders at the end of the reporting period[14] - The top shareholder, Tianjin Jinhao Pharmaceutical Co., Ltd., holds 50.93% of the shares, totaling 93,710,608 shares[14] Investment and Market Strategy - The company reported a significant increase in non-operating income, with a rise of 192.71% in gains from fixed asset disposals[12] - The company’s investment income increased by 49.54% due to higher returns from redeemed financial products[12] - The company plans to expand its market presence and is considering the sale of equity in Tianjin Pharmaceutical Group Financial Co., Ltd., which has seen a 18522.41% increase in held-for-sale assets[12] Inventory and Receivables - Inventory levels decreased to CNY 170,732,488.14 from CNY 199,146,584.76, a decline of approximately 14.3%[17] - Accounts receivable increased to CNY 184,403,559.74 from CNY 118,041,499.31, representing a growth of about 56.1%[17] Accounting and Audit - The company has not undergone an audit for the third quarter report[27] - The report indicates that the company has not applied the new accounting standards for the current year[26]